January 23, 2023/Cancer

Research Shows Link Between Antibiotic Use and Ovarian Cancer Outcomes

Reassessing antibiotic dosage and type and restoring gut biome could improve survival rates

chemo_650x450

Antibiotics routinely used for ovarian cancer patients indiscriminately kill gut bacteria, leading to faster cancer progression and lower survival rates, according to a retrospective clinical analysis of patients conducted by Cleveland Clinic research.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The results, published in Cancer Research, challenge the standard of care for epithelial ovarian cancer (EOC), the leading cause of gynecologic cancer death. Although most ovarian cancer patients respond to chemotherapy, tumors recur in more than 80% of patients, leading to a survival rate of less than five years.

Antibiotics are crucial to treating bacterial infections during chemotherapy, but they kill bacteria that is essential for patients with ovarian cancer to respond to treatment. Selecting antibiotics or dosages proven to preserve more of the microbiome could preserve the balance of gut bacteria and prevent tumor progression or treatment resistance, says Ofer Reizes, PhD, Department of Cardiovascular & Metabolic Sciences at Cleveland Clinic and lead investigator on the study.

Built on earlier research, study focuses on gut microbiome

The research digs deeper into an earlier study of women with advanced EOC undergoing platinum chemotherapy, which was published by Cleveland Clinic Ob/Gyn and Women’s Health Institute in Gynecological Oncology.The findings of this study indicate that antibiotic treatment was associated with decreased progression-free survival and overall survival.

Dr. Reizes’ investigative team, including members of the Center for Microbiome and Human Health, Taussig Cancer Center and the Women’s Health Institute, focused its research on the gut microbiome and performed additional studies to show that reintroducing healthy bacteria into the gut is sufficient to slow down ovarian cancer growth and restore tumor sensitivity to chemotherapy.

Looking at this problem through the microbiome can help explain why some patients are initially resistant to chemotherapy, as well as guide the use of antibiotics in clinical practice, says Chad Michener, MD, Vice Chair for Ob/Gyn & Women’s Health Institute. Physicians need to be good stewards for antibiotics use, he says, and this study provides further evidence to support selecting targeted, short-term antibiotics to treat infections and considering when antibiotics for prophylaxis are necessary.

Potential for metabolites to restore balance

The study also serves as a starting point for research on how to most effectively rebuild gut colonies. Some patients might benefit from reintroduction of bacteria through procedures like fecal microbial transplantation, while others could rebalance their gut through specific types of probiotics or dietary changes.

Advertisement

“Maybe it’s as simple as giving probiotics when people have cleared their infection, but it may be more in-depth than that,” says Dr. Michener.

Dr. Reizes, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, says that the team is currently working on whether introducing specific metabolites produced by the bacteria, identified in the study, could be used to restore that balance. This study highlighted two potential metabolites that could play a role in sensitivity to treatment and suppressing tumor growth – Indole-3-propionic acid and indoxyl sulfate.

Advertisement

Related Articles

Female cancer patient receiving chemotherapy
Adoptive Immunotherapy is Being Studied in Ovarian Cancer

Trial examines novel approach for a disease with a high mortality rate

22-NEU-3204009-CQD-Hero-650×450
October 11, 2022/Neurosciences/Brain Tumor
Does Extended Use of Prophylactic Antibiotics Improve Nasal Healing After Endoscopic Transsphenoidal Surgery?

Randomized controlled trial finds no quality-of-life benefit after standard pituitary tumor surgery

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

Director of the Novel Cancer Therapeutics Center
May 2, 2024/Cancer/Innovations
Oncology Pharmacovigilance Clinic Expands Specialties

First-of-its-kind clinic for immune-related adverse events supports oncologists in managing severe side effects

Scrambler therapy for nerve pain
April 29, 2024/Cancer
Scrambler Technology Life Changing for Many Patients with Neuropathic Pain

Novel therapy “retrains” the brain to disrupt pain signals

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

Ad